Compare · BLUE vs MRNA
BLUE vs MRNA
Side-by-side comparison of bluebird bio Inc. (BLUE) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLUE and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $56.02B, about 106.1x BLUE ($527.9M).
- MRNA has hit the wire 20 times in the past 4 weeks while BLUE has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- bluebird bio Inc.
- Moderna Inc.
- Price
- $4.96-0.20%
- $140.21-3.65%
- Market cap
- $527.9M
- $56.02B
- 1M return
- -
- +137.08%
- 1Y return
- -
- +464.34%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- 2018
- News (4w)
- 0
- 20
- Recent ratings
- 25
- 25
bluebird bio Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent Ã-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. bluebird bio, Inc. has a strategic alliance with National Resilience, Inc. to research, development, and delivery of cell therapies. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest BLUE
- SEC Form 15-12G filed by bluebird bio Inc.
- SEC Form EFFECT filed by bluebird bio Inc.
- Chief Business & Legal Officer Vittiglio Joseph returned 5,625 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)
- Director Agwunobi John O returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Vachon Mark returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Colvin Richard A returned 6,666 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)
- Director Tita-Reid Najoh returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)
- President and CEO Obenshain Andrew returned 24,120 shares to the company and was granted 14,820 shares, closing all direct ownership in the company (SEC Form 4)
- Director Leiderman Elisabeth returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Jones-Burton Charlotte returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest MRNA
- Chief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 9% to 74,375 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 8% to 81,340 units (SEC Form 4) (withholding obligation)
- Chief Legal Officer Klinger Shannon Thyme sold $485,766 worth of shares (3,471 units at $139.95) as part of a pre-agreed trading plan, covered exercise/tax liability with 1,048 shares and exercised 5,637 shares at a strike of $19.06, increasing direct ownership by 2% to 75,247 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M covered exercise/tax liability with 1,197 shares and converted options into 2,475 shares, increasing direct ownership by 2% to 68,282 units (SEC Form 4) (for withholding tax)
- President Hoge Stephen converted options into 9,283 shares and covered exercise/tax liability with 4,489 shares, increasing direct ownership by 0.32% to 1,489,699 units (SEC Form 4) (tax liability)
- Moderna downgraded by Rothschild & Co Redburn with a new price target
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Moderna to Present at Upcoming Conferences in September 2026
- President Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax